Barinthus Biotherapeutics plc announced its financial results for 2025, reporting a net loss of $66.5 million. The company is progressing with its merger with Clywedog Therapeutics, expected to close in Q2 2026, enhancing its focus on autoimmune and metabolic diseases.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.